INVO BIOSCIENCE, INC. (OTCMKTS:IVOB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

INVO BIOSCIENCE, INC. (OTCMKTS:IVOB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

Item 5.02

Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
In the evening of April 5, 2017, Claude Ranoux submitted his
letter of resignation effective immediately as a member of the
Board of Directors to INVO Bioscience, Inc.s Board of Directors
Chairperson and CEO Kathleen Karloff. Claude Ranoux stated,
Recent events with respect to the operation of the Board of
Directors have limited my ability to effectively serve the
company as director.
Claude Ranoux did not serve on any committee of the Board of
Directors at the time of his resignation.
Due to disagreements on how to run the business, Claude Ranoux
had initially indicated that he wanted Kathleen Karloff be
replaced as an officer. Instead, as previously reported by the
Corporation, on September 20, 2016 the Board of Directors
replaced Claude Ranoux as President and Treasurer, and removed
Claude Ranoux as Chief Scientist, of the Corporation, with
Kathleen Karloff then being elected Chairman of the Board,
President and CEO, and Robert Bowdring being elected Treasurer
and Secretary of the Corporation. Claude Ranoux voted against
those changes.
Since those changes Dr. Ranoux has voted against virtually all
of the actions taken by the Board of Directors, which actions
were approved by Ms. Karloff and Mr. Bowdring. Due to these
disagreements, Dr. Ranoux has indicated his desire to replace
Ms. Karloff and Mr. Bowdring as directors as well as change the
Corporations management.
The Board of Directors believes Dr. Ranouxs resignation was
caused by Dr. Ranoux ceasing to be the President, Treasurer and
Chief Scientist of the Corporation, the election of Ms. Karloff
and Mr. Bowdring to their new officer positions.
Dr. Ranouxs resignation letter is attached as Exhibit 17
A special telephonic Board of Directors meeting was called at
7:00 PM April 5, 2017, at which the Board of Directors
discussed and accepted Claude Ranouxs resignation as a
director. The Board determined that it would review a list of
potential candidates to fill the vacancy created on the Board
of Directors by Dr. Ranouxs resignation. A Board of Directors
meeting had been previously scheduled for April 7, 2017.
INVO Bioscience would like to thank Claude Ranoux for his
efforts over the years.
Item 9.01
Financial Statements and Exhibits
Exhibit Number
Description
Resignation letter dated April 5, 2017.


About INVO BIOSCIENCE, INC. (OTCMKTS:IVOB)

INVO Bioscience, Inc. is a medical device company. The Company is focused on creating various treatments for patients diagnosed with infertility. The Company’s product, the INVOcell, is a medical device used in infertility treatment and is considered as an assisted reproductive technology (ART). INVOcell is an intravaginal culture (IVC) system used for preparing, holding and transferring human gametes or embryos during vaginal in vitro fertilization or intravaginal culture procedures (IVF/IVC). The INVOcell system consists of various components: INVOcell Culture Device, INVOcell Retention Device and INVOcell Holding Block. The INVO Procedure is a fertility treatment option allowing fertilization and early embryo development to take place inside the woman’s body. The INVO Procedure is an IVC or in vivo incubation assisted reproduction technique available.

INVO BIOSCIENCE, INC. (OTCMKTS:IVOB) Recent Trading Information

INVO BIOSCIENCE, INC. (OTCMKTS:IVOB) closed its last trading session up +0.010 at 0.360 with 3,770 shares trading hands.

An ad to help with our costs